Cholesterol drugs that are not statins
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Non-Statin Cholesterol Drugs: Emerging Alternatives
Introduction to Non-Statin Cholesterol Drugs
Cholesterol management is crucial for reducing the risk of atherosclerotic cardiovascular disease (ASCVD). While statins have been the cornerstone of cholesterol-lowering therapy, not all patients can tolerate them due to side effects such as muscle pain and increased diabetes risk. Fortunately, several non-statin drugs have emerged as effective alternatives for lowering low-density lipoprotein cholesterol (LDL-C).
Ezetimibe: Cholesterol Absorption Inhibitor
Mechanism and Efficacy
Ezetimibe works by inhibiting the absorption of cholesterol in the small intestine, leading to a reduction in LDL-C levels. It is often used in combination with statins to achieve further LDL-C reduction. Clinical trials have shown that ezetimibe can significantly lower LDL-C levels and provide cardiovascular benefits, especially when statins alone are insufficient.
Safety Profile
Ezetimibe is generally well-tolerated, with a safety profile comparable to placebo. It offers a viable option for patients who experience adverse effects from statins.
PCSK9 Inhibitors: Monoclonal Antibodies
Mechanism and Efficacy
PCSK9 inhibitors, such as alirocumab and evolocumab, are monoclonal antibodies that target and inhibit the PCSK9 protein. This inhibition increases the number of LDL receptors on liver cells, enhancing the clearance of LDL-C from the bloodstream. Studies have demonstrated that PCSK9 inhibitors can reduce LDL-C levels by up to 60% and significantly lower the risk of cardiovascular events.
Safety Profile
PCSK9 inhibitors are generally well-tolerated, with the most common side effects being injection site reactions. They are particularly useful for patients with familial hypercholesterolemia or those who cannot achieve target LDL-C levels with statins and ezetimibe alone.
Bempedoic Acid: ATP Citrate Lyase Inhibitor
Mechanism and Efficacy
Bempedoic acid (BDA) inhibits ATP citrate lyase, an enzyme involved in cholesterol synthesis in the liver. This action results in decreased LDL-C levels. Clinical trials have shown that BDA can reduce LDL-C by approximately 18% when used as monotherapy and by up to 28% when combined with ezetimibe.
Safety Profile
BDA is generally well-tolerated, with the most common side effects being upper respiratory tract infections and muscle spasms. It offers an alternative for patients who are statin-intolerant or require additional LDL-C lowering.
Inclisiran: Small Interfering RNA
Mechanism and Efficacy
Inclisiran is a small interfering RNA (siRNA) that targets the PCSK9 gene, leading to reduced production of the PCSK9 protein. This results in increased LDL receptor activity and lower LDL-C levels. Clinical trials have shown that inclisiran can reduce LDL-C levels by up to 50% with just two doses per year.
Safety Profile
Inclisiran is well-tolerated, with the most common side effects being mild injection site reactions. Its infrequent dosing schedule makes it a convenient option for long-term cholesterol management.
Conclusion
Non-statin cholesterol-lowering drugs such as ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran offer effective alternatives for patients who cannot tolerate statins or need additional LDL-C reduction. These drugs have demonstrated significant efficacy in lowering LDL-C levels and reducing cardiovascular risk, providing valuable options in the management of hypercholesterolemia.
Sources and full results
Most relevant research papers on this topic